We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Computer Algorithms Automatically Detect Malaria in Stained Blood Smears

By LabMedica International staff writers
Posted on 10 Aug 2015
An Israeli startup company has developed a computerized platform that detects anomalies in stained blood cell samples—such as those infected by the malaria parasite—faster and more accurately than the human eye.

Sight Diagnostics or SightDx (Jerusalem, Israel) was initiated in 2011 with six million USD obtained from crowd funding and several innovation investors. More...
This funding was used by a team comprising biologists, software experts, and engineers to develop vision-based algorithms to scan and analyze blood. Analysis was based on visible characteristics such as size, shape, fluorescence intensity, and morphology.

The algorithms were set to function within SightDx's Parasight platform, a high throughput instrument suitable for batch (up to 30 samples) and asynchronous loading. It was designed to be fully automated, simple to operate, and optimized for rapid testing and analysis.

The Parasight platform consists of a scanning and analyzing device as well as a sample preparation kit containing custom-built disposable plastic cartridges to create an efficient, standardized, and uniform version of the “thin blood smear”, that is easy to prepare within 15 seconds. These cartridges require only a small drop of blood that can be obtained with a finger-stick or from a tube. Parasight reports, in under three minutes, the diagnosis (Positive/Negative), parasitemia count (number of parasites per microliter), and speciation (determination of the specific species of malaria). Results are automatically transferred to the laboratory information system.

Trials using Parasight were conducted in several hospitals in India, South Africa, and France. Results showed that it was 99% accurate in sensitivity and 98% in specificity as compared to results of about 95% for human microscopists.

“Essentially, you try to do what the human eye does,” said Joseph Joel Pollak, CEO of Sight Diagnostics. “Computer vision-based devices have a camera, and the camera takes pictures of the blood. Then, algorithms analyze the scene.”

Related Links:

Sight Diagnostics



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Immunofluorescence Analyzer
IFA System
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.